NCT05053035Phase 2Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Study sponsor: Alector Inc. · ALEC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-10-28Actual
Enrollment · participants5Actual
Source updated2025-06-18Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview